Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Bio Cmn (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 17,040
  • Shares Outstanding, K 4,260
  • Annual Sales, $ 400 K
  • Annual Income, $ -16,950 K
  • 36-Month Beta 1.64
  • Price/Sales 41.64
  • Price/Cash Flow 0.00
  • Price/Book 0.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.64 +11.54%
on 05/15/17
5.58 -27.24%
on 05/02/17
-0.50 (-10.96%)
since 04/24/17
3-Month
3.64 +11.54%
on 05/15/17
18.88 -78.50%
on 03/28/17
-2.03 (-33.33%)
since 02/24/17
52-Week
3.64 +11.54%
on 05/15/17
50.70 -91.99%
on 06/10/16
-16.49 (-80.24%)
since 05/24/16

Most Recent Stories

More News
Bear of the Day: AMAG Pharmaceuticals (AMAG)

Bear of the Day: AMAG Pharmaceuticals (AMAG)

AKTX : 6.51 (-9.21%)
CBIO : 4.06 (+1.50%)
REGN : 458.24 (-0.68%)
AMAG : 19.25 (+6.35%)
Bear of the Day: AMAG Pharmaceuticals (AMAG)

Bear of the Day: AMAG Pharmaceuticals (AMAG)

AKTX : 6.51 (-9.21%)
CBIO : 4.06 (+1.50%)
REGN : 458.24 (-0.68%)
AMAG : 19.25 (+6.35%)
Catalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update

-- Raised ~$20 million through an underwritten equity offering --

CBIO : 4.06 (+1.50%)
Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy

Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy

PTCT : 12.58 (-6.81%)
SLCA : 38.39 (-1.64%)
PTEN : 22.06 (+0.36%)
CBIO : 4.06 (+1.50%)
DXC : 77.95 (-0.41%)
5 Stocks with Earnings Acceleration to Buy Now

Earnings acceleration should be viewed as a key metric for share price outperformance

PTCT : 12.58 (-6.81%)
SLCA : 38.39 (-1.64%)
PTEN : 22.06 (+0.36%)
CBIO : 4.06 (+1.50%)
DXC : 77.95 (-0.41%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.27 (-2.16%)
CBAY : 3.96 (+1.80%)
SAGE : 67.64 (+0.33%)
CBIO : 4.06 (+1.50%)
BNIKF : 0.1392 (+3.88%)
Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the closing of an underwritten...

CBIO : 4.06 (+1.50%)
Key Milestone Reached in Catalyst's Subcutaneous Factor IX Program

-- Milestone payment received with completion of IND-enabling toxicology studies --

CBIO : 4.06 (+1.50%)
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering

Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the pricing of an underwritten...

CBIO : 4.06 (+1.50%)
Today's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The markets weren't really what you would call bullish yesterday. Barring a few, most of the stocks seeing changes of as little as 0.2-0.5%, either in the green...

PTX : 4.46 (-1.98%)
CBIO : 4.06 (+1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Support & Resistance

2nd Resistance Point 4.65
1st Resistance Point 4.36
Last Price 4.06
1st Support Level 3.84
2nd Support Level 3.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.